[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.128.52. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
April 1994

The Mystery of Antiphospholipid Antibodies in Sneddon's Syndrome

Author Affiliations

Groupe Hospitalier Pitié-Salpêtrière 83 Boulevard de l'Hôpital 75013 Paris Cedex,N France

Paris, France

Arch Dermatol. 1994;130(4):519-520. doi:10.1001/archderm.1994.01690040127024
Abstract

Studies on the prevalence of antiphospholipid antibodies (aPL) in patients with Sneddon's syndrome (SNS) have provided very conflicting results.1-3 Antiphospholipid antibodies, ie, mainly anticardiolipin antibodies (aCL) and/or lupus anticoagulant, were found in 85% of the 41 patients investigated by Kalashnikova et al.1 On the other hand, a study by Zelger et al3 recently reported in the Archives failed to detect aPL in 21 patients with SNS. This discrepancy cannot result from a recruitment bias concerning patients with systemic lupus, since they were excluded in the series described by Kalashnikova et al and absent in the one by Zelger et al.1,3

The following several questions regarding the study by Zelger et al3 are thus prompted: (1) Considering the mention of the aPL antibody syndrome in the differential diagnosis section of their article, can they confirm that the presence of aPL was not an exclusion criterion for

First Page Preview View Large
First page PDF preview
First page PDF preview
×